<DOC>
	<DOCNO>NCT01200862</DOCNO>
	<brief_summary>This study design 2-part study , Part 1 open-label best determine appropriate dose level use Part 2 , randomize , double-blind , placebo control design . The study aim assess safety tolerability BGS649 , determine whether BGS649 able normalize testosterone level improve insulin sensitivity obese , hypogonadotropic hypogonadal ( OHH ) men</brief_summary>
	<brief_title>Safety Efficacy BGS649 Obese , Hypogonadotropic Hypogonadal Men</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<criteria>Males meet criterion obese , hypogonadotropic hypogonadism define : Patients Body Mass Index ( BMI ) ≥ 30 kg/m2 Patients morning serum total testosterone level &lt; 300 ng/dL least two separate occasion Screening and/or Baseline period . Patients inappropriately low gonadotropin screen give low testosterone : Luteinizing hormone ( LH ) ≤ ULN Follicle stimulate hormone ( FSH ) ≤ ULN Estradiol within normal range ( define ≥ LLN approve assay ) Normal hypothalamic/pituitary function , include : Prolactin : within normal range Thyroid stimulate hormone ( TSH ) : within normal range Ferritin : within normal range Patients agree use barrier method contraception ( e.g. , condom ) , duration study least 3 month follow Study Completion visit prevent BGS649 exposure partner . Patients hypogonadism , relate obesity result underlie issue Patients significant major organ class illness ( e.g . kidney liver disease ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Obese</keyword>
	<keyword>obesity</keyword>
	<keyword>hypogonadism</keyword>
	<keyword>hypogonadotropic</keyword>
	<keyword>hyperestrogenemic</keyword>
	<keyword>testosterone</keyword>
	<keyword>hypogonadal</keyword>
</DOC>